Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Akero Therapeutics, Inc. stock logo
AKRO
Akero Therapeutics
$56.19
-0.2%
$47.62
$21.02
$58.40
$4.48B-0.161.04 million shs3.83 million shs
Amedisys, Inc. stock logo
AMED
Amedisys
$97.92
-0.1%
$95.28
$82.15
$98.95
$3.21B0.94418,468 shs397,167 shs
Convey Health Solutions Holdings, Inc. stock logo
CNVY
Convey Health Solutions
$10.51
$10.51
$3.75
$10.73
$769.27M-0.3219,508 shsN/A
Merus N.V. stock logo
MRUS
Merus
$52.99
-0.4%
$48.89
$33.19
$62.98
$3.67B1.04743,249 shs457,851 shs
Beginner's Guide To Retirement Stocks Cover

Enter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Akero Therapeutics, Inc. stock logo
AKRO
Akero Therapeutics
0.00%+3.67%+10.13%+38.81%+139.51%
Amedisys, Inc. stock logo
AMED
Amedisys
0.00%+0.47%+3.74%+5.71%+6.67%
Convey Health Solutions Holdings, Inc. stock logo
CNVY
Convey Health Solutions
0.00%0.00%0.00%0.00%0.00%
Merus N.V. stock logo
MRUS
Merus
0.00%-0.21%-4.85%+25.90%-10.44%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Akero Therapeutics, Inc. stock logo
AKRO
Akero Therapeutics
3.528 of 5 stars
3.51.00.04.71.90.80.0
Amedisys, Inc. stock logo
AMED
Amedisys
2.6516 of 5 stars
1.11.00.05.02.01.71.3
Convey Health Solutions Holdings, Inc. stock logo
CNVY
Convey Health Solutions
N/AN/AN/AN/AN/AN/AN/AN/A
Merus N.V. stock logo
MRUS
Merus
1.9401 of 5 stars
3.61.00.00.02.02.50.0
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Akero Therapeutics, Inc. stock logo
AKRO
Akero Therapeutics
3.00
Buy$82.5046.82% Upside
Amedisys, Inc. stock logo
AMED
Amedisys
2.20
Hold$100.752.89% Upside
Convey Health Solutions Holdings, Inc. stock logo
CNVY
Convey Health Solutions
0.00
N/AN/AN/A
Merus N.V. stock logo
MRUS
Merus
3.14
Buy$84.6459.72% Upside

Current Analyst Ratings Breakdown

Latest CNVY, AMED, AKRO, and MRUS Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
5/27/2025
Akero Therapeutics, Inc. stock logo
AKRO
Akero Therapeutics
Bank of America
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$63.00 ➝ $64.00
5/23/2025
Merus N.V. stock logo
MRUS
Merus
BMO Capital Markets
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Set Price TargetOutperform ➝ Outperform$96.00 ➝ $110.00
5/19/2025
Merus N.V. stock logo
MRUS
Merus
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$75.00 ➝ $75.00
5/13/2025
Akero Therapeutics, Inc. stock logo
AKRO
Akero Therapeutics
Citigroup
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$80.00 ➝ $78.00
5/8/2025
Merus N.V. stock logo
MRUS
Merus
Wells Fargo & Company
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOverweight ➝ Overweight$91.00 ➝ $89.00
4/28/2025
Merus N.V. stock logo
MRUS
Merus
William Blair
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform
4/16/2025
Amedisys, Inc. stock logo
AMED
Amedisys
Royal Bank Of Canada
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform ➝ Outperform$100.00 ➝ $100.00
4/9/2025
Merus N.V. stock logo
MRUS
Merus
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$83.00 ➝ $83.00
(Data available from 6/30/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Akero Therapeutics, Inc. stock logo
AKRO
Akero Therapeutics
N/AN/AN/AN/A$10.75 per shareN/A
Amedisys, Inc. stock logo
AMED
Amedisys
$2.35B1.37$6.23 per share15.71$36.03 per share2.72
Convey Health Solutions Holdings, Inc. stock logo
CNVY
Convey Health Solutions
$337.60M2.28$0.46 per share22.90$7.35 per share1.43
Merus N.V. stock logo
MRUS
Merus
$54.73M67.01N/AN/A$9.46 per share5.60
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Akero Therapeutics, Inc. stock logo
AKRO
Akero Therapeutics
-$252.06M-$1.95N/AN/AN/AN/A-15.19%-13.97%8/8/2025 (Estimated)
Amedisys, Inc. stock logo
AMED
Amedisys
$43.23M$2.7136.1320.231.333.79%12.52%7.01%7/23/2025 (Estimated)
Convey Health Solutions Holdings, Inc. stock logo
CNVY
Convey Health Solutions
-$9.98M-$0.10N/A25.63N/A-1.90%0.08%0.05%N/A
Merus N.V. stock logo
MRUS
Merus
-$215.33M-$4.08N/AN/AN/A-506.73%-35.99%-29.83%7/30/2025 (Estimated)

Latest CNVY, AMED, AKRO, and MRUS Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
7/23/2025Q2 2025
Amedisys, Inc. stock logo
AMED
Amedisys
$1.39N/AN/AN/A$614.61 millionN/A
5/14/2025Q1 2025
Merus N.V. stock logo
MRUS
Merus
-$1.17-$1.40-$0.23-$1.40$7.82 million$26.49 million
5/12/2025Q1 2025
Akero Therapeutics, Inc. stock logo
AKRO
Akero Therapeutics
-$1.01$0.90+$1.91$0.90N/AN/A
4/23/2025Q1 2025
Amedisys, Inc. stock logo
AMED
Amedisys
$1.13$1.25+$0.12$1.84$597.43 million$594.78 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Akero Therapeutics, Inc. stock logo
AKRO
Akero Therapeutics
N/AN/AN/AN/AN/A
Amedisys, Inc. stock logo
AMED
Amedisys
N/AN/AN/AN/AN/A
Convey Health Solutions Holdings, Inc. stock logo
CNVY
Convey Health Solutions
N/AN/AN/AN/AN/A
Merus N.V. stock logo
MRUS
Merus
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Akero Therapeutics, Inc. stock logo
AKRO
Akero Therapeutics
0.03
16.80
16.80
Amedisys, Inc. stock logo
AMED
Amedisys
0.27
1.29
1.29
Convey Health Solutions Holdings, Inc. stock logo
CNVY
Convey Health Solutions
0.50
2.20
1.60
Merus N.V. stock logo
MRUS
Merus
N/A
5.86
5.86

Institutional Ownership

CompanyInstitutional Ownership
Akero Therapeutics, Inc. stock logo
AKRO
Akero Therapeutics
N/A
Amedisys, Inc. stock logo
AMED
Amedisys
94.36%
Convey Health Solutions Holdings, Inc. stock logo
CNVY
Convey Health Solutions
85.28%
Merus N.V. stock logo
MRUS
Merus
96.14%

Insider Ownership

CompanyInsider Ownership
Akero Therapeutics, Inc. stock logo
AKRO
Akero Therapeutics
7.07%
Amedisys, Inc. stock logo
AMED
Amedisys
2.10%
Convey Health Solutions Holdings, Inc. stock logo
CNVY
Convey Health Solutions
6.20%
Merus N.V. stock logo
MRUS
Merus
4.57%
CompanyEmployeesShares OutstandingFree FloatOptionable
Akero Therapeutics, Inc. stock logo
AKRO
Akero Therapeutics
3079.72 million74.08 millionOptionable
Amedisys, Inc. stock logo
AMED
Amedisys
19,00032.82 million32.13 millionOptionable
Convey Health Solutions Holdings, Inc. stock logo
CNVY
Convey Health Solutions
3,80073.19 million68.66 millionNot Optionable
Merus N.V. stock logo
MRUS
Merus
3769.21 million66.05 millionOptionable

Recent News About These Companies

Merus N.V.: Making Progress
Why Merus N.V. (MRUS) Crashed On Wednesday
Merus Shares Slide on Stock Offering

New MarketBeat Followers Over Time

Media Sentiment Over Time

Akero Therapeutics stock logo

Akero Therapeutics NASDAQ:AKRO

$56.19 -0.09 (-0.16%)
Closing price 06/27/2025 04:00 PM Eastern
Extended Trading
$56.18 -0.02 (-0.03%)
As of 06/27/2025 07:34 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Akero Therapeutics, Inc., together with its subsidiary, engages in the development of treatments for patients with serious metabolic diseases in the United States. The company's lead product candidate is efruxifermin (EFX), which is in Phase 3 clinical trials that protects against cellular stress and regulates the metabolism of lipids, carbohydrates, and proteins throughout the body for the treatment of biopsy-confirmed metabolic dysfunction-associated steatohepatitis (MASH) patients. It has a license agreement with Amgen Inc. to develop, manufacture, use, distribute, and sell EFX as a treatment for MASH and other metabolic diseases. The company was formerly known as Pippin Pharmaceuticals, Inc. and changed its name to Akero Therapeutics, Inc. in May 2018. Akero Therapeutics, Inc. was incorporated in 2017 and is headquartered in South San Francisco, California.

Amedisys stock logo

Amedisys NASDAQ:AMED

$97.92 -0.11 (-0.11%)
Closing price 06/27/2025 04:00 PM Eastern
Extended Trading
$95.00 -2.92 (-2.98%)
As of 04:05 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Amedisys, Inc., together with its subsidiaries, provides healthcare services in the United States. It operates through three segments: Home Health, Hospice, and High Acuity Care. The Home Health segment offers a range of services in the homes of individuals for the recovery of patients from surgery, chronic disability, or terminal illness, as well as prevents avoidable hospital readmissions through its skilled nurses; nursing services, rehabilitation therapists specialized in physical, speech, and occupational therapy; and social workers and aides for assisting its patients. The Hospice segment offers services that is designed to provide comfort and support for those who are dealing with a terminal illness, including cancer, heart disease, pulmonary disease, or Alzheimer's. The High Acuity Care offers essential elements of inpatient hospital, skilled nursing facility care, and palliative care to patients in their homes. Amedisys, Inc. was incorporated in 1982 and is headquartered in Baton Rouge, Louisiana.

Convey Health Solutions stock logo

Convey Health Solutions NYSE:CNVY

Convey Health Solutions Holdings, Inc. provides technology enabled solutions and advisory services to assist its clients with workflows across product developments, sales, member experience, clinical management, core operations, and business intelligence and analytics. It operates through two segments, Technology Enabled Solutions and Advisory Services. The Technology Enabled Solutions segment offers technology solutions through web-based customizable application that is used to identify, track, and administer contractual services, or benefits provided under a client's plan to its Medicare and Medicaid beneficiaries. It also provides analytics over healthcare data to capture and assess gaps in risk documentation, quality, clinical care, and compliance. The company also offers health plan management, data analytics, supplemental benefit, advisory, and software services. The Advisory Services segment offers sales and marketing strategies, provider network strategies, compliance, star ratings, quality, clinical, pharmacy, analytics, and risk adjustment. It serves government sponsored, medicare advantage, medicare, as well as pharmacy benefits managers. The company was founded in 2001 and is headquartered in Fort Lauderdale, Florida. Convey Health Solutions Holdings, Inc. is a former subsidiary of TPG Cannes Aggregation, L.P.

Merus stock logo

Merus NASDAQ:MRUS

$52.99 -0.19 (-0.36%)
Closing price 06/27/2025 04:00 PM Eastern
Extended Trading
$52.94 -0.05 (-0.08%)
As of 04:00 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Merus N.V., a clinical-stage immuno-oncology company, engages in the development of antibody therapeutics in the Netherlands. Its bispecific antibody candidate pipeline includes Zenocutuzumab (MCLA-128), which is in a phase 2 clinical trials for the treatment of patients with metastatic breast cancer and castration-resistant prostate cancer, as well as in Phase 1/2 clinical trials for the treatment of solid tumors that harbor Neuregulin 1. The company is also developing MCLA-158, which is in a phase I clinical trial for the treatment of solid tumors; MCLA-145, which is in phase 1 clinical trials for the treatment of solid tumors; MCLA-129, which is in phase 1/2 clinical trials for the treatment of patients with advanced non-small cell lung cancer and other solid tumors; and ONO-4685 that is Phase 1 clinical trial to treat relapsed/refractory T cell lymphoma. In addition, it has collaboration agreement with Betta Pharmaceuticals Co. Ltd for the research and development of stage bispecific antibody candidates include MCLA-129; collaboration with Incyte Corporation for the development of MCLA-145; and collaboration with Gilead Sciences, Inc. to discover novel antibody-based trispecific T-cell engagers. The company was incorporated in 2003 and is headquartered in Utrecht, the Netherlands.